What are Nrf2 activator drugs?

Nrf2 activator drugs are pharmacologic agents that share a common mechanism (typically targeting Nrf2 (NFE2L2)). 0 are currently marketed, with 2 more in clinical development.

Nrf2 activator

0 marketed 2 in Phase 3

This page covers all Nrf2 activator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Nrf2 (NFE2L2).

Targets

Nrf2 (NFE2L2)

Phase 3 pipeline (2)

Etavopivat A · Novo Nordisk A/S · Hematology/Oncology
Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase fetal hemoglobin (HbF) production and reduce hemolysis in patients with sickle cell disease.
Etavopivat Tablets High dose · Forma Therapeutics, Inc. · Hematology/Rare Blood Disorders
Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase antioxidant defenses and reduce hemolysis in red blood cells.